Pemetrexed (Alimta®) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Gemcitabine (2′,2′-difluorodeoxycytidine) is a pyrimidine antimetabolite with broad activity in a variety of solid tumors including breast cancer. Pemetrexed (Alimta®) is a novel, multitargeted antifolate that inhibits 3 folate-dependent enzymes, and is also broadly active in a wide variety of solid tumors. In breast cancer, pemetrexed has activity in patients previously treated with anthracyclines and taxanes, and pemetrexed demonstrates pre-clinical and clinical cytotoxic synergy with gemcitabine. This drug combination is being evaluated in a phase II study for the treatment of metastatic breast cancer patients who have previously received a taxane and an anthracycline.

Original languageEnglish (US)
Pages (from-to)S21-S23
JournalClinical breast cancer
Volume3
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 1 2002

Keywords

  • Anthracyclines
  • Gemcitabine
  • Multitargeted antifolate
  • Pemetrexed
  • Taxanes
  • Vitamin supplementation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pemetrexed (Alimta®) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes'. Together they form a unique fingerprint.

  • Cite this